Baidu
map

用于区分血流感染与成人斯蒂尔病的生物标志物筛查和验证:一项前瞻性队列研究

2022-01-11 MedSci原创 MedSci原创

区分 BSI 和风湿性疾病,尤其是成人斯蒂尔病 (AOSD),仍然很困难。生物标志物筛查或许可以提供一个思路。

血流感染(BSI) 是世界范围内导致死亡的主要原因,受影响的患者数量持续增加、。BSI 疾病负担与成人的严重外伤、心肌梗塞和中风造成的负担相当 。BSI 的临床表现包括尖峰热、突然发冷、呼吸急促心动过速、皮疹、肝脾肿大和精神变化。

BSI 可能由革兰氏阳性或阴性细菌引起。两者都含有复杂的细胞壁表面聚合物肽聚糖(PGN),它是细菌细胞壁的主要成分。磷壁酸(TA)是革兰氏阳性菌表面的多糖聚合物,按其锚定位置可分为脂磷壁酸(LTA)和壁磷壁酸(WTA)。革兰氏阴性菌也含有表面脂多糖(LPS)。PGN、LTA和LPS可以作为表面抗原,刺激外周血中的细胞,促进炎性细胞因子的释放。

AOSD 是一种罕见的、来源不明的全身性自身炎症性疾病,伴有高热、短暂性皮疹、关节痛、喉咙痛、淋巴结肿大、肝脾肿大和肌痛 。

阳性血培养仍然是 BSI 诊断的金标准。然而,血培养需要 ≥ 48-72 小时,可能会产生假阴性结果。此外,区分 BSI 和风湿性疾病,尤其是成人斯蒂尔病 (AOSD),仍然很困难。

方法

纳入标准为:(1)体温≥38℃,白细胞 ≥9.5×10 /L,中性粒细胞%≥75%,(2)入院时进行血培养。

排除标准为:(1)3个月内接受糖皮质激素/其他免疫抑制药物治疗的患者,(2)获得性免疫缺陷综合征/其他免疫性疾病患者,(3)入院6小时内死亡的患者。血样采集于乙二胺四乙酸 抗凝剂中入院时符合条件的患者的管子。

64 人参加了训练集(BSI 37 人,AOSD 17 人,健康对照组 10 人)。此外,86 人被纳入验证队列(BSI 67 人,AOSD 19 人)。收集临床和实验室数据。使用细菌特异性抗原刺激血样,并通过 Luminex 或酶联免疫吸附测定法检测上清液中几种细胞因子的水平。

结果

大肠杆菌肺炎克雷伯菌是导致 BSI 最常见的病原体。在训练队列中,AOSD 患者皮疹、关节痛、肌痛、喉咙痛、淋巴结病、白细胞增多和高铁蛋白血症的发生率高于 BSI 患者。BSI 患者的降钙素原显着高于 AOSD 患者。BSI 患者的白细胞介素 (IL)-6、IL-17A、C-X3-C 基序趋化因子配体 (CX3CL)-1 和 CXC 基序趋化因子配体 10 (CXCL10) 水平高于 AOSD 患者。AOSD 患者的 IL-18 高于 BSI 患者。决策树分析表明,血浆 IL-18 和铁蛋白水平的组合可用于区分 BSI 和 AOSD(诊断准确度:97.67%,敏感性:96.15%,特异性:100%)。

训练队列中病原体的分布

表:训练和验证队列中BSI和 AOSD患者的临床表现和常规实验室检查

结论

几种血浆细胞因子被确定为潜在的非侵入性生物标志物,以区分 BSI 和 AOSD。BSI患者血浆IL-6、IL-17A、CX3CL1和CXCL10水平高于AOSD患者,而AOSD患者血浆IL-18水平高于BSI患者。研究血浆 IL-18 和铁蛋白水平的组合可能具有更大的诊断潜力,此外,IL-18 可能是 BSI 和 AOSD 预后预测的潜在生物标志物。

来源:Wei Zhang, Tao Yang, Haocheng Zhang, Yuzhen Xu, Qingluan Yang, Qianqian Liu, Yan Gao, Jing Wu, Lingyun Shao, Wenhong Zhang,Biomarker screening and validation for the differentiation of bloodstream infection from adult-onset Still’s disease: A prospective cohort study,Cytokine,Volume 146,2021,155642,ISSN 1043-4666,
https://doi.org/10.1016/j.cyto.2021.155642.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2006548, encodeId=26dc200654896, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Thu Jun 30 13:49:27 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937641, encodeId=7c88193e64108, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Sun Sep 18 20:49:27 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954332, encodeId=b8001954332a6, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Feb 12 23:49:27 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841805, encodeId=3c1c184180512, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Jul 03 20:49:27 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511884, encodeId=319a1511884e4, content=<a href='/topic/show?id=d88b891e376' target=_blank style='color:#2F92EE;'>#血流感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89173, encryptionId=d88b891e376, topicName=血流感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83b410387887, createdName=ms6829001416292975, createdTime=Thu Jan 13 06:49:27 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561109, encodeId=69941561109b9, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Thu Jan 13 06:49:27 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567118, encodeId=b125156e11800, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Thu Jan 13 06:49:27 CST 2022, time=2022-01-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2006548, encodeId=26dc200654896, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Thu Jun 30 13:49:27 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937641, encodeId=7c88193e64108, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Sun Sep 18 20:49:27 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954332, encodeId=b8001954332a6, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Feb 12 23:49:27 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841805, encodeId=3c1c184180512, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Jul 03 20:49:27 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511884, encodeId=319a1511884e4, content=<a href='/topic/show?id=d88b891e376' target=_blank style='color:#2F92EE;'>#血流感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89173, encryptionId=d88b891e376, topicName=血流感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83b410387887, createdName=ms6829001416292975, createdTime=Thu Jan 13 06:49:27 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561109, encodeId=69941561109b9, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Thu Jan 13 06:49:27 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567118, encodeId=b125156e11800, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Thu Jan 13 06:49:27 CST 2022, time=2022-01-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2006548, encodeId=26dc200654896, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Thu Jun 30 13:49:27 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937641, encodeId=7c88193e64108, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Sun Sep 18 20:49:27 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954332, encodeId=b8001954332a6, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Feb 12 23:49:27 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841805, encodeId=3c1c184180512, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Jul 03 20:49:27 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511884, encodeId=319a1511884e4, content=<a href='/topic/show?id=d88b891e376' target=_blank style='color:#2F92EE;'>#血流感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89173, encryptionId=d88b891e376, topicName=血流感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83b410387887, createdName=ms6829001416292975, createdTime=Thu Jan 13 06:49:27 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561109, encodeId=69941561109b9, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Thu Jan 13 06:49:27 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567118, encodeId=b125156e11800, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Thu Jan 13 06:49:27 CST 2022, time=2022-01-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2006548, encodeId=26dc200654896, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Thu Jun 30 13:49:27 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937641, encodeId=7c88193e64108, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Sun Sep 18 20:49:27 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954332, encodeId=b8001954332a6, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Feb 12 23:49:27 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841805, encodeId=3c1c184180512, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Jul 03 20:49:27 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511884, encodeId=319a1511884e4, content=<a href='/topic/show?id=d88b891e376' target=_blank style='color:#2F92EE;'>#血流感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89173, encryptionId=d88b891e376, topicName=血流感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83b410387887, createdName=ms6829001416292975, createdTime=Thu Jan 13 06:49:27 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561109, encodeId=69941561109b9, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Thu Jan 13 06:49:27 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567118, encodeId=b125156e11800, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Thu Jan 13 06:49:27 CST 2022, time=2022-01-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2006548, encodeId=26dc200654896, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Thu Jun 30 13:49:27 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937641, encodeId=7c88193e64108, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Sun Sep 18 20:49:27 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954332, encodeId=b8001954332a6, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Feb 12 23:49:27 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841805, encodeId=3c1c184180512, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Jul 03 20:49:27 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511884, encodeId=319a1511884e4, content=<a href='/topic/show?id=d88b891e376' target=_blank style='color:#2F92EE;'>#血流感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89173, encryptionId=d88b891e376, topicName=血流感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83b410387887, createdName=ms6829001416292975, createdTime=Thu Jan 13 06:49:27 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561109, encodeId=69941561109b9, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Thu Jan 13 06:49:27 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567118, encodeId=b125156e11800, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Thu Jan 13 06:49:27 CST 2022, time=2022-01-13, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2006548, encodeId=26dc200654896, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Thu Jun 30 13:49:27 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937641, encodeId=7c88193e64108, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Sun Sep 18 20:49:27 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954332, encodeId=b8001954332a6, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Feb 12 23:49:27 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841805, encodeId=3c1c184180512, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Jul 03 20:49:27 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511884, encodeId=319a1511884e4, content=<a href='/topic/show?id=d88b891e376' target=_blank style='color:#2F92EE;'>#血流感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89173, encryptionId=d88b891e376, topicName=血流感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83b410387887, createdName=ms6829001416292975, createdTime=Thu Jan 13 06:49:27 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561109, encodeId=69941561109b9, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Thu Jan 13 06:49:27 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567118, encodeId=b125156e11800, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Thu Jan 13 06:49:27 CST 2022, time=2022-01-13, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2006548, encodeId=26dc200654896, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Thu Jun 30 13:49:27 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937641, encodeId=7c88193e64108, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Sun Sep 18 20:49:27 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954332, encodeId=b8001954332a6, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Feb 12 23:49:27 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841805, encodeId=3c1c184180512, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Jul 03 20:49:27 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511884, encodeId=319a1511884e4, content=<a href='/topic/show?id=d88b891e376' target=_blank style='color:#2F92EE;'>#血流感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89173, encryptionId=d88b891e376, topicName=血流感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83b410387887, createdName=ms6829001416292975, createdTime=Thu Jan 13 06:49:27 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561109, encodeId=69941561109b9, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Thu Jan 13 06:49:27 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567118, encodeId=b125156e11800, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Thu Jan 13 06:49:27 CST 2022, time=2022-01-13, status=1, ipAttribution=)]

相关资讯

短暂性脑缺血发作伴长奈瑟菌血流感染报道1例

长奈瑟菌为奈瑟菌属,革兰阴性球菌,是上呼吸 道正常菌群之一?该菌为条件致病菌,造成感染的情 况少见且相关病例资料少,目前国内仅发现2例长奈 瑟菌感染且均为硝酸盐还原亚种[ 1 -2],因此研究者对 其

血流感染分离出1例毗邻颗粒链菌

颗粒链菌属对营养要求苛刻,对于血平板上生长不良的链球菌,应考虑颗粒链菌属的可能,可加做卫星试验,或接种在添加半胱氨酸或盐酸毗邻醛的培养基中,以免漏诊或误诊。

2019年肾脏基金会会议:研究性新药Neutrolin显著降低血液透析时的血流感染

CorMedix是一家生物制药公司,致力于开发和商业化预防和治疗传染病和炎症性疾病的治疗产品。CorMedix近日宣布,前瞻性、多中心、双盲、主动控制的III期试验(LOCK-IT-100研究)的中期分析结果将在2019年肾脏基金会会议上公布。

如何预防中心静脉导管相关血流感染?

一些慢性疾病患者因治疗所需,将长期放置中心静脉导管。如果发生中心静脉导管(CVCs)相关的血流感染(BSI)将导致患者死亡率、患病率增加,并增加治疗成本,因此,预防中心静脉导管相关血流感染意义重大,

Stroke:脓毒症和血流感染患者脑卒中的危险因素

由此可见,卒中的危险因素和综合风险评分可能有助于确定脓毒症患者的亚群,这些脓毒症患者的目标可能是降低严重感染后卒中的短期风险。

证据:如何预防中心静脉导管相关血流感染?

临床问题如何预防中心静脉导管相关血流感染?临床问题一些慢性疾病患者因治疗所需,将长期放置中心静脉导管。如果发生中心静脉导管(CVCs)相关的血流感染(BSI)将导致患者死亡率、患病率增加,并增加治疗成本,因此,预防中心静脉导管相关血流感染意义重大,现将有关证据汇总如下。证据描述●一项meta分析表明,使用葡萄糖酸氯己定(CHG)溶液进行局部消毒比使用聚维酮碘(PI)溶液减少约49%的住院患者导

Baidu
map
Baidu
map
Baidu
map